This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bhandari, M. S. Articles by Hussain, M. Search for Related Content PubMed PubMed Citation Articles by Bhandari, M. S. Articles by Hussain, M.

Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?

Manish S. Bhandari, Juanita Crook, Maha Hussain

From the Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI; and the Department of Radiation Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Canada

Address reprint requests to Maha Hussain, MD, FACP, University of Michigan, 1500 East Medical Center Dr, 7314 CCGC, Ann Arbor, MI 48109-0946; e-mail: mahahuss{at}umich.edu.

For several decades, androgen deprivation (AD) has been the mainstay for treating metastatic prostate cancer. AD can be attained by a variety of means; however, irrespective of modality and a gratifying initial high response rate, almost all patients advance to a state of androgen independence and ultimately a hormone-refractory state. Improved understanding of the biology and mechanisms of progression to androgen independence coupled with promising preclinical data have led to investigating intermittent AD (IAD) as a way of improving disease control while maintaining quality of life. Preliminary published clinical experience, mostly from uncontrolled trials, suggests the feasibility of this approach. Two ongoing cooperative-group phase III trials are evaluating the survival impact of IAD both in patients with metastatic disease and in those with prostate-specific antigen failure post–radiation therapy. There are several unanswered questions regarding this approach, and until more definitive data regarding its safety and impact on survival are available, IAD should be considered experimental. In this review, we detail the background and preclinical scientific rational for investigating IAD, and we review published clinical experience and describe the ongoing phase III clinical trials. We also discuss special considerations for using IAD outside the context of a clinical trial.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				V. B. Shahinian, Y.-f. Kuo, J. L. Freeman, E. Orihuela, and J. S. Goodwin Characteristics of Urologists Predict the Use of Androgen Deprivation Therapy for Prostate Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5359 - 5365. [Abstract] [Full Text] [PDF]

				E. J. Small and E. A. Klein Challenges and Future Directions in the Prevention and Management of Prostate Cancer J. Clin. Oncol., November 10, 2005; 23(32): 8143 - 8145. [Full Text] [PDF]